Evidence map›Paper›PMID 36246105›Full record

ArticleFrontiers in physiology2022

Assessing potency and binding kinetics of soluble adenylyl cyclase (sAC) inhibitors to maximize therapeutic potential.

Thomas Rossetti, Jacob Ferreira, Lubna Ghanem, Hannes Buck, Clemens Steegborn, Robert W Myers, Peter T Meinke, Lonny R Levin, Jochen Buck

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Frontiers in physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. The uniqueness of on-demand male contraception.Molecular aspects of medicine · 2024
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Thomas RossettiDepartment of Pharmacology, Weill Cornell Medicine, New York, NY, United States.
Jacob FerreiraDepartment of Pharmacology, Weill Cornell Medicine, New York, NY, United States.
Lubna GhanemDepartment of Pharmacology, Weill Cornell Medicine, New York, NY, United States.
Hannes BuckDepartment of Pharmacology, Weill Cornell Medicine, New York, NY, United States.
Clemens SteegbornDepartment of Biochemistry, University of Bayreuth, Bayreuth, Germany.
Robert W MyersTri-Institutional Therapeutics Discovery Institute, New York, NY, United States.
Peter T MeinkeTri-Institutional Therapeutics Discovery Institute, New York, NY, United States.
Lonny R LevinDepartment of Pharmacology, Weill Cornell Medicine, New York, NY, United States.
Jochen BuckDepartment of Pharmacology, Weill Cornell Medicine, New York, NY, United States.
Cornell University · USTri-Institutional Therapeutics Discovery Institute · USUniversity of Bayreuth · DEWeill Cornell Medicine · US

Funding

Crosstalk between metabolic and signaling pathways involved in sperm capacitationR01HD088571 · NICHD · WEILL MEDICAL COLL OF CORNELL UNIV · PI JOCHEN BUCK, LONNY R LEVIN · 2017 to 2026
$6.1M
Optimization and pre-clinical evaluation of ADCY10 inhibitorsP50HD100549 · NICHD · WEILL MEDICAL COLL OF CORNELL UNIV · PI LEVIN, LONNY R · 2019 to 2021
$6.0M
High Throughput screen to identify "first of their kind" activators of ADCY10R01AG061290 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI BUCK, JOCHEN, LEVIN, LONNY R · 2019 to 2022
$2.3M
Discovery and Characterization of an Endogenous Inhibitor of Soluble Adenylyl CyclaseF31HD105363 · NICHD · WEILL MEDICAL COLL OF CORNELL UNIV · PI FERREIRA, JACOB · 2021 to 2023
$140k
Activation of Soluble Adenylyl Cyclase as a Novel Therapeutic Strategy for the Treatment of Age-Related Neurodegenerative DisordersF31AG069501 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI ROSSETTI, THOMAS · 2020 to 2022
$129k
NIA NIH HHS F31 AG069501NIA NIH HHS R01 AG061290NICHD NIH HHS F31 HD105363NICHD NIH HHS P50 HD100549NICHD NIH HHS R01 HD088571
6 · The paper itself

Abstract

In mammalian cells, 10 different adenylyl cyclases produce the ubiquitous second messenger, cyclic adenosine monophosphate (cAMP). Amongst these cAMP-generating enzymes, bicarbonate (HCO

Indexed as

binding kineticsdrug developmentlead optimizationmale contraceptivepicomolar potencyresidence timesoluble adenylyl cyclaseSPR

Identifiers

PMID36246105
PMCPMC9554468
OpenAlexW4297544175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.